Scarica l'app Stockscreener
0.8225
2.98%
-0.0253
Precedente Chiudi:
$0.8478
Aprire:
$0.8478
Volume 24 ore:
206.15K
Relative Volume:
1.44
Capitalizzazione di mercato:
$34.34M
Reddito:
$14.92M
Utile/perdita netta:
$-86.88M
Rapporto P/E:
-0.2679
EPS:
-3.0699
Flusso di cassa netto:
$-82.31M
1 W Prestazione:
-6.87%
1M Prestazione:
-16.07%
6M Prestazione:
-41.67%
1 anno Prestazione:
-68.12%
Intervallo 1D:
$0.82
$0.8593
Intervallo di 1 settimana:
$0.82
$0.91
Portata 52W:
$0.80
$3.16
Carisma Therapeutics Inc Stock (CARM) Company Profile
Nome
Carisma Therapeutics Inc
Settore
Industria
Telefono
(267) 491-6422
Indirizzo
3675 MARKET STREET, PHILADELPHIA
Confronta CARM con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
| CARM | 0.8225 | 34.34M | 14.92M | -86.88M | -82.31M | -3.0699 |
| VRTX | 450.97 | 116.14B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 738.00 | 81.10B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 605.92 | 36.23B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 244.89 | 31.59B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 113.13 | 27.12B | 3.30B | -501.07M | 1.03B | 11.54 |
Carisma Therapeutics Inc Stock (CARM) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2023-07-06 | Iniziato | Evercore ISI | Outperform |
| 2023-05-31 | Aggiornamento | Jefferies | Hold → Buy |
| 2023-05-24 | Iniziato | H.C. Wainwright | Buy |
| 2023-04-14 | Iniziato | Robert W. Baird | Outperform |
Carisma Therapeutics Inc Borsa (CARM) Ultime notizie
Carisma Therapeutics to Present New Data on Anti-GPC3 In Vivo CA - GuruFocus.com
Carisma Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights - GuruFocus.com
Carisma Therapeutics Presents Promising New Preclinical Data on Engineered Macrophages for the Treatment of Liver Fibrosis at AASLD The Liver Meeting® 2024 - PR Newswire
Carisma Therapeutics Reports Q3 2024 Results, Advances Clinical Programs - MSN
Carisma Therapeutics stock a buy at D. Boral Capital, HER2 & platform value in focus - Investing.com India
Carisma Therapeutics and Moderna Unveil Promising Pre-Clinical Data for Anti-GPC3 CAR-M Therapy - MSN
Carisma Therapeutics Third Quarter 2024 Earnings: Misses Expectations - Simply Wall St
Carisma reports progress in liver cancer therapy development - Investing.com India
Carisma reports progress in liver cancer therapy development By Investing.com - Investing.com Australia
Carisma Therapeutics reports data from its CAR-M therapy - TipRanks
Carisma Therapeutics Inc. Unveils Promising Pre-Clinical Data on Anti-Gpc3 in Vivo Car-M Therapy for Hepatocellular Carcinoma - Marketscreener.com
Carisma Therapeutics reports Q3 EPS (31c), consensus (26c) - TipRanks
Carisma Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
CARISMA Therapeutics Inc Reports Q3 2024 Revenue of $3.39M and G - GuruFocus.com
Carisma Therapeutics Welcomes Sohanya Cheng to Board of Directors - MSN
Carisma Therapeutics to Present New Data on Anti-GPC3 In Vivo CAR-M Therapy for Hepatocellular Carcinoma at SITC 2024 - Citizentribune
Carisma to present new data on CAR-M therapy for hepatocellular carcinoma - TipRanks
Carisma Therapeutics (NASDAQ:CARM) Upgraded at EF Hutton Acquisition Co. I - Defense World
Carisma shares climb on EF Hutton Buy rating - Investing.com India
Carisma Therapeutics Appoints Sohanya Cheng to Board of Directors - citybiz
Carisma Therapeutics names Sohanya Cheng to board - Investing.com India
Carisma Therapeutics Announces Changes to its Board of Directors - Quantisnow
Carisma Therapeutics Reports Second Quarter 2024 Financial Resul - GuruFocus.com
Carisma Therapeutics faces Nasdaq delisting over market value By Investing.com - Investing.com Australia
Carisma Therapeutics faces Nasdaq delisting over market value - Investing.com
Carisma Therapeutics to Showcase Cutting-Edge Cancer Research at SITC 2024 - MSN
Carisma Therapeutics Announces Upcoming Presentations at SITC 2024 - Yahoo Finance
Carly Rae Jepsen is engaged! Canadian singer shares happy news on social media: 'Very engaged over here' - Yahoo Canada Shine On
Carly Rae Jepsen Flaunts Blue Engagement Ring with Grammy Winning Fiancé - 2paragraphs Buzz
CRDF (Cardiff Oncology Inc) has impressive results - US Post News
Berkley W R Corp Sells 451,295 Shares of Cartica Acquisition Corp (NASDAQ:CITE) - MarketBeat
Carly Rae Jepsen is a fiancée! Singer announces engagement to Grammy-winning producer - USA TODAY
Carly Rae Jepsen Engaged to Producer Cole MGN: See Her RingE! Online - E! NEWS
'Very engaged over here': Singer Carly Rae Jepsen announces her engagement to music producer Cole M.G.N. - 9Honey Celebrity
Investing in Aclaris Therapeutics Inc (ACRS) Is Getting More Attractive - Knox Daily
Surprise! Carly Rae Jepsen Is Engaged!!! - PerezHilton.com
Nasdaq-Traded Cannabinoid Biotech Corbus Pharma Stock Plunges 60%, But Analysts Say 'Buy The Dip' Now - Benzinga
Carly Rae Jepsen announces engagement to boyfriend Cole MGN after two years of dating - Daily Mail
Carly Rae Jepsen Proclaims Herself ‘Very Engaged Over Here’ in Photoshoot Showing Off Ring From Fiancé Cole M.G.N. - Billboard
Carly Rae Jepsen Engaged to Producer Cole M.G.N. - AceShowbiz Media
Carly Rae Jepsen & Boyfriend Cole M.G.N. Are Engaged! - Just Jared
Cole M.G.N. Entertainment News, Photos, and Videos - Just Jared
A closer look at Cara Therapeutics Inc (CARA) is warranted - US Post News
Hancock Whitney Corp Has $737,000 Stock Holdings in Corcept Therapeutics Incorporated (NASDAQ:CORT) - Defense World
Where Are They Now? Carisma Therapeutics - Life Science Leader Magazine
Gabelli Funds LLC Has $120.74 Million Stake in Crane (NYSE:CR) - MarketBeat
Corbus Pharmaceuticals (NASDAQ:CRBP) PT Lowered to $40.00 at B. Riley - Defense World
Cosmic CRF shares hit 5% upper circuit on Rs 127-crore order win; details - Business Standard
Carisma Therapeutics Inc Azioni (CARM) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.89%
2.08%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):